A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Japanese encephalitis (JE) live attenuated vaccine SA14-14-2 has been in use for more more than 20 years in Asia. JE vaccine SA14-14-2 is licensed in India and has been widely used since 2006. JE vaccines give protection by generating a neutralizing antibody response, but both naturally exposed persons and patients with JE also have T cell responses. Whether JE vaccine SA14-14-2 elicits T cell responses is unknown. This study tests the hypothesis that T cell responses are generated in response to JE SA14-14-2 vaccination. The aim of this study is to characterize T cell responses to JE vaccine SA14-14-2 in healthy people, and to investigate differences in T cell responses between natural exposure, vaccination and disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas

NCT06678373

Japanese Encephalitis

ACTIVE_NOT_RECRUITING PHASE4

Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis

NCT06825312

Japanese Encephalitis Vaccine

ACTIVE_NOT_RECRUITING PHASE4

Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province

NCT04817917

Japanese Encephalitis Vaccine Preventable Disease Vaccine Reaction

UNKNOWN PHASE4

Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children

NCT01408537

Encephalitis, Japanese B

COMPLETED PHASE3

Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

NCT02602652

Japanese Encephalitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Japanese Encephalitis Japanese Encephalitis Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine

Single dose live attenuated Japanese encephalitis vaccine SA14-14-2

Group Type EXPERIMENTAL

Live attenuated Japanese encephalitis vaccine SA14-14-2

Intervention Type BIOLOGICAL

Live attenuated Japanese encephalitis vaccine SA14-14-2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Live attenuated Japanese encephalitis vaccine SA14-14-2

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A male or female adult between 18 and 50 years of age.
* Written informed consent.
* Free of obvious health problems as established by medical history and history- directed physical examination before entering the study.
* Expected continuous residence in India during study period, without travel outside India
* An efficacious method of contraception must be used during the study for women of childbearing potential.

Exclusion Criteria

* Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding administration of SA14-14-2 vaccine, or planned use during the study period.
* Chronic administration of immunosuppressants or other immune-modifying drugs within a period of six months before vaccination or at any time during the study period.
* Any confirmed or suspected immunosuppressive or immunodeficient condition.
* A family history of congenital or hereditary immunodeficiency.
* Any antiviral drug therapy within a period of six months before vaccination or at any time during the study period.
* History of significant allergic disease or reactions likely to be exacerbated by any component of the study vaccine, especially allergic disease or reactions to any previous dose of any vaccine.
* History of having received JE vaccine, yellow fever vaccine, tick-borne encephalitis vaccine or experimental flavivirus vaccine.
* History of documented JE infection.
* Detectable anti JE or West Nile neutralizing antibodies in screening tests.
* Acute disease at the time of enrollment. Entry into the study may be deferred until the illness is resolved.
* Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, neurological or renal functional abnormality, as determined by history and physical or laboratory examination that is not controlled by drugs.
* Administration of immunoglobulins and/or any blood products within the three months preceding administration of vaccine, or planned administration during the study period.
* Seropositive for HIV, HCV or HbsAg.
* Lactation, pregnancy or intention to get pregnant.
* History of excessive alcohol consumption, drug abuse or significant psychiatric illness.
* Any other condition that in the opinion of the investigator would pose a health risk to the participant or interfere with the evaluation of the vaccine.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes